Table 4b.
Univariate and multivariate analysis for progression-free survival of visceral metastasis
| Variables | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|
| n | Median (95% CI) | p-Value | Exp (B) (95% CI) | p-Value | ||
| Age at Fulvestrant | ||||||
| < 50 | 48 | 4.9 (2.1-7.7) | 0.026 | 0.612 | ||
| ≥ 50 | 159 | 7.8 (6.0-9.6) | ||||
| Menopause status at Fulvestrant | ||||||
| Premenopausal# | 34 | 5.1 (2.2-7.9) | 0.18 | 0.763 | ||
| Postmenopausal | 173 | 7.7 (6.1-9.3) | ||||
| DFS | ||||||
| < 2 years | 16 | 5.8 (3.6-8.1) | 0.007 | 0.005 | ||
| 2-5 years | 26 | 3.5 (1.1-6.0) | 1.31 (0.67-2.54) | 0.427 | ||
| > 5 years | 139 | 8.1 (6.3-9.9) | 2.52 (1.51-4.22) | <0.001 | ||
| Number of metastatic sites | ||||||
| 1-2 | 65 | 8.9 (3.9-13.9) | 0.005 | 0.004 | ||
| 3-4 | 106 | 7.7 (5.6-9.9) | 0.38 (0.22-0.66) | 0.001 | ||
| ≥ 5 | 36 | 4.0 (2.9-5.1) | 0.53 (0.32-0.88) | 0.014 | ||
| Previous chemotherapy for metastatic breast cancer | ||||||
| None | 64 | 9.4 (3.9-14.9) | 0.001 | 0.064 | ||
| 1 or 2 lines | 112 | 5.7 (3.9-7.4) | ||||
| ≥ 3 lines | 31 | 3.5 (1.9-5.1) | ||||
| Liver metastases | ||||||
| Yes | 82 | 4.6 (3.1-6.1) | <0.001 | 0.52 (0.35-0.78) | 0.001 | |
| No | 125 | 9.3 (5.4-13.2) | ||||
| Lung metastases | ||||||
| Yes | 137 | 8.9 (7.7-10.1) | 0.008 | 0.266 | ||
| No | 70 | 4.7 (3.6-5.9) | ||||
| Brain metastases | ||||||
| Yes | 13 | 5.1 (2.8-7.3) | 0.175 | 0.664 | ||
| No | 194 | 7.7 (6.2-9.3) | ||||
| Bone metastases | ||||||
| Yes | 149 | 6.2 (4.6-7.9) | 0.031 | 0.423 | ||
| No | 58 | 10.6 (5.2-15.9) | ||||
CI: confidence interval; DFS: disease-free survival.
#Premenopausal patients received ovarian function suppression in duration of Fulvestrant treatment.